Cross Country Healthcare reported Q4 2022 consolidated revenue of $628.2 million, a slight decrease year-over-year and quarter-over-quarter. Diluted EPS was $1.05, compared to $2.07 in the prior year and $0.93 in the prior quarter. Net income attributable to common stockholders was $38.8 million, down from $77.6 million in the prior year and up from $34.8 million in the prior quarter.
Fourth quarter consolidated revenue was $628.2 million, a slight decrease from the prior year and prior quarter.
Consolidated gross profit margin was 22.1%, down 90 basis points year-over-year and 50 basis points sequentially.
Diluted earnings per share (EPS) was $1.05 compared to $2.07 in the prior year and $0.93 in the prior quarter.
Adjusted EPS was $1.09 compared to $1.40 in the prior year and $1.07 in the prior quarter.
The guidance below applies only to management’s expectations for the first quarter of 2023. We reaffirm our 2023 annual targets of a minimum $2.2 billion in revenue and $200 million in Adjusted EBITDA.
Visualization of income flow from segment revenue to net income